IP Library › Assignment 054976/0294
Patent Assignment
Reel/Frame 054976/0294

Change of Name

Recorded: 2021-01-12 Pages: 7
Assignor
PORTOLA PHARMACEUTICALS, INC.
Executed: 2020-10-15
Assignee
PORTOLA PHARMACEUTICALS, LLC
270 E. GRAND AVE., SOUTH SAN FRANCISCO, CALIFORNIA, 94080
Covered Properties (139)
Platelet Adp Receptor Inhibitors
Piperazine and Homopiperazine Compounds
Substituted Isoquinolinones
2,4-Dioxo-3-Quinazolinylaryl Sulfonylureas
Substituted 2H-1,3-Benzoxazin-4(3H)-Ones
Tetrahydroisoquinolines as Factor Xa Inhibitors
Ureas as Factor Xa Inhibitors
Thioureas as Factor Xa Inhibitors
Device and Methods for Identifying and Treating Aspirin Non-Responsive Patients
Substituted-(Quinazolinyl)Phenyl Thiophenyl-Sulfonylureas, Methods for Making and Intermediates Thereof
[4-(6-Halo-7-Substituted-2,4-Dioxo-1,4-Dihydro-2H-Quinazolin-3-Yl)-Phenyl]-5-Chloro-Thiophen-2-Yl-Sulfonylureas and Forms and Methods Related Thereto
Potassium Channel Modulators and Platelet Procoagulant Activity
Platelet Adp Receptor Inhibitors
Targeted Delivery and Expression of Procoagulant Hemostatic Activity
Intravenous and Oral Dosing of a Direct-Acting and Reversible P2Y12 Inhibitor
Combination Therapy with a Compound Acting as a Platelet Adp Receptor Inhibitor
Use of Tp Modulators for the Treatment of Cardiovascular Disorders in Aspirin Sensitive and Other Populations
Unit Dose Formulations and Methods of Treating and Preventing Thrombosis with Thromboxane Receptor Antagonists
[4-(6-Fluoro-7-Methylamino-2,4-Dioxo-1,4-Dihydro-2H-Quinazolin-3-Yl)-Phenyl]-5-Chloro-Thiophen-2-Yl-Sulfonylurea Salts, Forms and Methods Related Thereto
[4-(6-Fluoro-7-Methylamino-2,4-Dioxo-1,4-Dihydro-2H-Quinazolin-3-Yl)-Phenyl]-5-Chloro-Thiophen-2-Yl-Sulfonylurea Salts, Forms and Methods Related Thereto
Solid Composition for Controlled Release of Ionizable Active Agents with Poor Aqueous Solubility at Low Ph and Methods of Use Thereof
Test Cartridges for Flow Assays and Methods for Their Use
Inhibitors of Jak
Methods for Diagnosis and Treatment of Thrombotic Disorders Mediated by 2C19*2
Methods of Synthesizing Factor Xa Inhibitors
Pharmaceutical Composition and Dosage Forms of Elinogrel and Methods of Use Thereof
Dosage Forms of Elinogrel and Methods of Injectable Administration Thereof
Crystalline Forms of a Factor Xa Inhibitor
Methods and Formulations of Treating Thrombosis with Betrixaban and a P-Glycoprotein Inhibitor
Nicotinamides as Jak Kinase Modulators
Prevention and Treatment of Thrombosis in Medically Ill Patients
Pyridazine Compounds as Jak Inhibitors
Isotopically Enriched Betrixaban
Methods of Identifying Agents That Modulate P2Y12 Receptor Activity
Patent: 6,762,029 →
Application: 09/745,842 →
Publication: US 2003/0170777
Platelet Adp Receptor Inhibitors
Application: 09/775,812 →
Publication: US 2002/0025961
Platelet Adp Receptor Inhibitors
Patent: 6,906,063 →
Application: 09/920,325 →
Publication: US 2002/0077486
4-Thieno[2,3-D]Pyrimidin-4-Yl Piperazine Compounds
Patent: 7,115,741 →
Application: 10/237,153 →
Publication: US 2003/0153556
Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
Application: 10/275,154 →
Publication: US 2004/0029867
Platlet Adp Receptor Inhibitors
Patent: 6,689,786 →
Application: 10/350,883 →
Publication: US 2003/0162774
Platelet Adp Receptor Inhibitors
Patent: 7,022,731 →
Application: 10/759,396 →
Publication: US 2004/0147576
Platelet Adp Receptor Inhibitors
Patent: 7,056,926 →
Application: 10/941,053 →
Publication: US 2005/0228029
2,4-Dioxo-3-Quinazolinylaryl Sulfonylureas
Patent: 7,109,332 →
Application: 10/956,004 →
Publication: US 2005/0107357
Substituted Isoquinolinones
Patent: 7,294,635 →
Application: 10/956,006 →
Publication: US 2005/0113399
Substituted 2H-1,3-Benzoxazin-4(3H)-Ones
Patent: 7,205,296 →
Application: 11/236,051 →
Publication: US 2006/0069093
Tetrahydroisoquinolines as Factor Xa Inhibitors
Patent: 7,612,089 →
Application: 11/284,805 →
Publication: US 2006/0160840
Platelet Adp Receptor Inhibitors
Patent: 7,678,790 →
Application: 11/286,259 →
Publication: US 2007/0155719
Platelet Adp Receptor Inhibitors
Patent: 7,358,257 →
Application: 11/293,026 →
Publication: US 2006/0194795
Thioureas as factor Xa inhibitors
Application: 11/298,296 →
Publication: US 2006/0160790
Ureas as Factor Xa Inhibitors
Patent: 7,678,913 →
Application: 11/298,317 →
Publication: US 2006/0160821
Device and Methods for Identifying and Treating Aspirin Non-Responsive Patients
Patent: 7,358,091 →
Application: 11/304,054 →
Publication: US 2006/0160165
[4-(6-Halo-7-Substituted-2,4-Dioxo-1,4-Dihydro-2H-Quinazolin-3-Yl)-Phenyl]-5-Chloro-Thiophen-2-Yl-Sulfonylureas and Forms and Methods Related Thereto
Patent: 8,058,284 →
Application: 11/556,490 →
Publication: US 2007/0123547
Substituted-(Quinazolinyl)Phenyl Thiophenyl-Sulfonylureas, Methods for Making and Intermediates Thereof
Application: 11/556,518 →
Publication: US 2007/0208045
Platelet Adp Receptor Inhibitors
Patent: 7,622,474 →
Application: 11/841,711 →
Publication: US 2008/0194597
Substituted Dihydroquinazolines as Platelet Adp Receptor Inhibitors
Patent: 7,834,023 →
Application: 11/856,616 →
Publication: US 2008/0132499
Device and Methods for Identifying and Treating Aspirin Non-Responsive Patients
Patent: 7,785,891 →
Application: 12/037,012 →
Publication: US 2008/0207681
Targeted Delivery and Expression of Procoagulant Hemostatic Activity
Application: 12/057,100 →
Publication: US 2008/0241233
Intravenous and Oral Dosing of a Direct-Acting and Reversible P2Y12 Inhibitor
Application: 12/114,630 →
Publication: US 2009/0048216
Use of Tp Modulators for the Treatment of Cardiovascular Disorders in Aspirin Sensitive and Other Populations
Application: 12/114,642 →
Publication: US 2009/0012115
Unit Dose Formulations and Methods of Treating and Preventing Thrombosis with Thromboxane Receptor Antagonists
Application: 12/114,646 →
Publication: US 2009/0012136
Combination Therapy with a Compound Acting as a Platelet Adp Receptor Inhibitor
Application: 12/114,706 →
Publication: US 2008/0279845
[4-(6-Fluoro-7-Methylamino-2,4-Dioxo-1,4-Dihydro-2H-Quinazolin-3-Yl)-Phenyl]-5-Chloro-Thiophen-2-Yl-Sulfonylurea Salts, Forms and Methods Related Thereto
Application: 12/114,742 →
Publication: US 2009/0042916
[4-(6-Fluoro-7-Methylamino-2,4-Dioxo-1,4-Dihydro-2H-Quinazolin-3-Yl)-Phenyl]-5-Chloro-Thiophen-2-Yl-Sulfonylurea Salts, Forms and Methods Related Thereto
Application: 12/265,699 →
Publication: US 2009/0156620
Potassium Channel Modulators and Platelet Procoagulant Activity
Application: 12/280,531 →
Publication: US 2009/0186810
Platelet Adp Receptor Inhibitors
Patent: 8,067,428 →
Application: 12/559,389 →
Publication: US 2010/0234350
SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF
Application: 12/618,511 →
Publication: US 2010/0151019
Platelet Adp Receptor Inhibitors
Application: 12/642,379 →
Publication: US 2011/0212983
Inhibitors of Jak
Patent: 8,367,689 →
Application: 12/775,358 →
Publication: US 2011/0005947
Combination Therapy with a Compound Acting as a Platelet Adp Receptor Inhibitor
Patent: 8,946,219 →
Application: 12/908,837 →
Publication: US 2011/0033459
Substituted Dihydroquinazolines as Platelet Adp Receptor Inhibitors
Application: 12/912,367 →
Publication: US 2011/0098247
Methods of Synthesizing Factor Xa Inhibitors
Patent: 8,394,964 →
Application: 12/969,371 →
Publication: US 2011/0319627
Test Cartridges for Flow Assays and Methods for Their Use
Application: 13/139,714 →
[4-(6-Fluoro-7-Methylamino-2,4-Dioxo-1,4-Dihydro-2H-Quinazolin-3-Yl)-Phenyl]-5-Chloro-Thiophen-2-Yl-Sulfonylurea Salts, Forms and Methods Related Thereto
Application: 13/166,763 →
Publication: US 2012/0129876
CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR
Patent: 8,946,269 →
Application: 13/223,023 →
Publication: US 2012/0071519
Methods and Formulations of Treating Thrombosis with Betrixaban and a P-Glycoprotein Inhibitor
Application: 13/223,038 →
Publication: US 2012/0095019
Intravenous and Oral Dosing of a Direct-Acting and Reversible P2Y12 Inhibitor
Application: 13/235,305 →
Publication: US 2012/0009172
Platelet Adp Receptor Inhibitors
Patent: 8,524,721 →
Application: 13/270,193 →
Publication: US 2012/0149688
[4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto
Application: 13/271,037 →
Publication: US 2012/0088736
Nicotinamides as Jak Kinase Modulators
Patent: 9,102,625 →
Application: 13/286,984 →
Publication: US 2012/0108566
Methods for Diagnosis and Treatment of Thrombotic Disorders Mediated by CYP2C19*2
Application: 13/383,402 →
Pharmaceutical Composition and Dosage Forms of Elinogrel and Methods of Use Thereof
Application: 13/521,906 →
Publication: US 2013/0165459
Solid Composition for Controlled Release of Ionizable Active Agents with Poor Aqueous Solubility at Low Ph and Methods of Use Thereof
Application: 13/633,055 →
Publication: US 2013/0172374
Dosage Forms of Elinogrel and Methods of Injectable Administration Thereof
Application: 13/695,428 →
Publication: US 2013/0131089
Inhibitors of Jak
Patent: 8,853,230 →
Application: 13/717,569 →
Publication: US 2013/0137673
METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS
Patent: 8,987,463 →
Application: 13/757,483 →
Publication: US 2013/0211094
Platelet Adp Receptor Inhibitors
Application: 13/956,251 →
Publication: US 2014/0221405
Pharmaceutical Compositions, Dosage Forms and New Forms of the Compound of Formula (I), and Methods of Use Thereof
Patent: 8,987,285 →
Application: 13/990,632 →
Publication: US 2013/0252979
Methods and Formulations of Treating Thrombosis with Betrixaban and a P-Glycoprotein Inhibitor
Application: 14/078,415 →
Publication: US 2014/0323497
Prevention and Treatment of Thrombosis in Medically Ill Patients
Application: 14/241,824 →
Publication: US 2015/0224091
Nicotinamides as Jak Kinase Modulators
Application: 14/754,389 →
Publication: US 2015/0353495
Pyridazine Compounds as Jak Inhibitors
Patent: 9,834,548 →
Application: 15/118,433 →
Publication: US 2017/0174673
Prevention and Treatment of Thrombosis in Medically Ill Patients
Application: 15/456,133 →
Publication: US 2018/0028510
Prevention and Treatment of Thrombosis in Medically Ill Patients
Application: 16/256,909 →
Publication: US 2020/0016133
Methods of Prevention and Treatment of Thrombosis
Application: 16/427,209 →
Publication: US 2019/0388406
Novel Adp Receptor
Application: 60/171,622 →
Platelet adp receptor inhibitors
Application: 60/180,208 →
Platelet adp receptor inhibitors
Application: 60/202,072 →
Benzofused platelet ADP receptor inhibitors
Application: 60/202,075 →
Platelet ADP receptor inhibitors
Application: 60/230,447 →
Benzofused platelet adp receptor inhibitors
Application: 60/230,456 →
Bicyclic fused heterocyclic platelet ADP receptor inhibitors
Application: 60/317,192 →
Substituted isoquinolinones
Application: 60/508,402 →
2,4-Dioxo-3-quinazolinylaryl sulfonylureas
Application: 60/508,564 →
Substituted 2H-1,3-benzoxazin-4(3H)-ones
Application: 60/614,564 →
Tetrahydroisoquinolines as factor Xa inhibitors
Application: 60/629,836 →
Thioureas as factor Xa inhibitors
Application: 60/634,150 →
Ureas as factor Xa inhibitors
Application: 60/634,201 →
Device and methods for identifying and treating aspirin non-responsive patients
Application: 60/636,744 →
[4-(6-Halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
Application: 60/733,650 →
K+ channel inhibitors and platelet procoagulant activity
Application: 60/786,163 →
Potassium channel modulators and platelet procoagulant activity
Application: 60/794,106 →
Platelet ADP receptor inhibitors
Application: 60/846,328 →
Targeted Delivery and Expression of Procoagulant Hemostatic Activity
Application: 60/908,575 →
Intravenous and Oral Dosing of a Direct-Acting and Reversible P2Y12 Inhibitor
Application: 60/915,649 →
Use of Tp Modulators for the Treatment of Cardiovascular Disorders in Aspirin Sensitive and Other Populations
Application: 60/915,784 →
Unit Dose Formulations and Methods of Treating Thrombosis with Thromboxane Receptor Antagonists
Application: 60/915,785 →
Combination Therapy with a Compound Acting as a Platelet Adp Receptor Inhibitor
Application: 60/915,911 →
[4-6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
Application: 60/927,328 →
Use of Tp Modulators for the Treatment of Cardiovascular Disorders in Aspirin Sensitive and Other Populations
Application: 60/947,289 →
Unit Dose Formulations and Methods of Treating Thrombosis with Thromboxane Receptor Antagonists
Application: 60/947,316 →
Intravenous Dosing a Direct-Acting and Reversible P2Y12 Inhibitor
Application: 60/947,921 →
Combination Therapy with a Compound Acting as a Platelet Adp Receptor Inhibitor
Application: 60/978,700 →
SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF
Application: 61/115,008 →
Test Cartridges for Flow Assays and Methods for Their Use
Application: 61/122,634 →
Inhibitors of Jak
Application: 61/176,077 →
Methods for Diagnosis and Treatment of Thrombotic Disorders Mediated by 2C19*2
Application: 61/224,839 →
Inhibitors of Jak
Application: 61/256,239 →
Pharmaceutical Composition and Dosage Forms of Elinogrel and Methods of Use Thereof
Application: 61/294,385 →
Methods for Diagnosis and Treatment of Thrombotic Disorders Mediated by 2C19*2
Application: 61/321,596 →
Pharmaceutical Composition and Dosage Forms of Elinogrel and Methods of Use Thereof
Application: 61/329,709 →
Dosage Forms of Elinogrel and Methods of Injectable Administration Thereof
Application: 61/329,725 →
Pharmaceutical Composition and Dosage Forms of Elinogrel and Methods of Use Thereof
Application: 61/334,068 →
Methods and Formulations of Treating Thrombosis with a Factor Xa Inhibitor and a P-Glycoprotein Inhibitor
Application: 61/379,339 →
Benzamides and Nicotinamides as Jak Modulators
Application: 61/409,030 →
CRYSTALLINE POLYMORPHS OF A FACTOR Xa INHIBITOR
Application: 61/454,396 →
Methods and Formulations of Treating Thrombosis with a Factor Xa Inhibitor and a P-Glycoprotein Inhibitor
Application: 61/454,402 →
Prevention and Treatment of Thrombosis in Medically Ill Patients
Application: 61/529,755 →
Pyridazine Compounds as Jak Inhibitors
Application: 61/939,859 →
Deuterium-Enriched Betrixaban
Application: 62/259,298 →
Methods of Prevention and Treatment of Thrombosis
Application: 62/678,951 →
Related Assignments (13)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jun 11, 2012
From: MERCK SHARP & DOHME CORP.
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 028356/0211 →
Assignment of Assignor's Interest Oct 19, 2012
From: LI, HUI; WANG, JUAN; LAMBING, JOE
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 029159/0669 →
Assignment of Assignor's Interest Oct 29, 2012
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 029206/0792 →
Assignment of Assignor's Interest Oct 29, 2012
From: NOVARTIS AG
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 029206/0843 →
Assignment of Assignor's Interest Feb 4, 2013
From: TAILLEMITE, JULIEN; FILLIOT, MARIE-PIERRE; BECKER, DIETER
To: NOVARTIS PHARMA AG
Reel/Frame 029750/0816 →
Assignment of Assignor's Interest Feb 6, 2013
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 029767/0434 →
Assignment of Assignor's Interest Feb 6, 2013
From: NOVARTIS AG
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 029768/0114 →
Assignment of Assignor's Interest Mar 11, 2013
From: RAMANI, CHANDIR; VADAS, ELIZABETH
To: PATHEON, INC.
Reel/Frame 029967/0702 →
Assignment of Assignor's Interest Mar 11, 2013
From: PATHEON, INC.
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 029965/0909 →
Confirmatory License Aug 24, 2016
From: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
To: NIH-DEITR
Reel/Frame 039528/0688 →
Security Interest Mar 18, 2019
From: PORTOLA PHARMACEUTICALS, INC.
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 048633/0673 →
Release of Security Interest Jul 2, 2020
From: HCR COLLATERAL MANAGEMENT, LLC
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 053120/0925 →
Assignment of Assignor's Interest Jan 12, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054975/0203 →